These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28494405)

  • 1. Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?
    Brighenti M; Petrelli F; Barni S; Conti B; Sarti E; Ratti M; Panni S; Passalacqua R; Bersanelli M
    Eur J Cancer; 2017 Jul; 79():149-151. PubMed ID: 28494405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
    Juan O; Popat S
    Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
    BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
    Ashworth A; Rodrigues G; Boldt G; Palma D
    Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
    Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
    Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.
    Bansal P; Rusthoven C; Boumber Y; Gan GN
    Future Oncol; 2016 Dec; 12(23):2713-2727. PubMed ID: 27467543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of treatment options for oligometastatic non-small cell lung cancer.
    Folkert MR; Timmerman R
    Clin Adv Hematol Oncol; 2015 Mar; 13(3):186-93. PubMed ID: 26352427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
    Langer F; Helsberg K; Schütte WH; Leschinger MI
    Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer.
    Guerrero E; Ahmed M
    Lung Cancer; 2016 Feb; 92():22-8. PubMed ID: 26775592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined modality therapy of non-small cell lung cancers.
    Juretic A; Sobat H; Samija M
    Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving role of radiotherapy in treatment of oligometastatic NSCLC.
    Bergsma DP; Salama JK; Singh DP; Chmura SJ; Milano MT
    Expert Rev Anticancer Ther; 2015; 15(12):1459-71. PubMed ID: 26536370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic radiotherapy in oligometastatic cancer.
    Kennedy TAC; Corkum MT; Louie AV
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Oligometastatic Disease in Advanced Non-Small Cell Lung Cancer.
    West H
    Clin Chest Med; 2020 Jun; 41(2):249-258. PubMed ID: 32402360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC).
    Khan AJ; Mehta PS; Zusag TW; Bonomi PD; Penfield Faber L; Shott S; Abrams RA
    Radiother Oncol; 2006 Nov; 81(2):163-7. PubMed ID: 17050016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing Patients With Oligometastatic Non-Small-Cell Lung Cancer.
    Stephens SJ; Moravan MJ; Salama JK
    J Oncol Pract; 2018 Jan; 14(1):23-31. PubMed ID: 29324212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of node-negative oligometastatic non-small cell lung cancer.
    Sakai K; Takeda M; Hayashi H; Tanaka K; Okuda T; Kato A; Nishimura Y; Mitsudomi T; Koyama A; Nakagawa K
    Thorac Cancer; 2016 Nov; 7(6):670-675. PubMed ID: 27755813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
    Su S; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y; Wang X; Li T; Li J; Chen M; Lu Y; Bai Y; He Z; Lu B
    BMC Cancer; 2016 Nov; 16(1):908. PubMed ID: 27871270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial.
    Tibdewal A; Agarwal JP; Srinivasan S; Mummudi N; Noronha V; Prabhash K; Patil V; Purandare N; Janu A; Kannan S
    BMJ Open; 2021 Mar; 11(3):e043628. PubMed ID: 33727268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
    Bunn PA
    Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.